It is of note that disruption of Arg‐II does not affect plasma concentration of cholesterol, triglycerides, or insulin, nor does it affect body weight gain, which suggests that Arg‐II ablation protects against type II diabetes mellitus independently of the plasma parameters and obesity, which can be attributed to decreased chronic systemic inflammation in insulin‐responsive tissues. This evidence concerns the gene INS and obesity due to melanocortin 4 receptor deficiency.